GlassScriptPhysician profile
Roya A Azadi
NPI 1912180084
$7,696.29
in general payments reported to CMS, 2019-2025
35 companies · $2,063 in 2025
The $2,063 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $897 · 2021: $764 · 2022: $1,104 · 2023: $1,379 · 2024: $873 · 2025: $2,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,314.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,522.44 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $930.40 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $721.31 | 2023-2025 | |
| Novo Nordisk INC | $678.77 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.92 | 2020-2025 | Jardiance |
| Galderma Laboratories, L.P. | $363.11 | 2021-2025 | |
| Amgen INC. | $300.31 | 2022-2025 | Otezla, Repatha, Repatha |
| Ibsa Pharma INC. | $264.34 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $254.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $253.36 | 2023-2024 | Quviviq |
| Mannkind Corporation | $222.79 | 2019-2022 | |
| Allergan, INC. | $218.30 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.87 | 2019-2021 | |
| Astellas Pharma US INC | $176.58 | 2019-2025 | Veozah |
| Radius Health, INC. | $165.90 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $150.13 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $142.34 | 2025 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $120.02 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $107.26 | 2023 | Nuedexta |
| Amneal Pharmaceuticals LLC | $78.98 | 2025 | Unithroid |
| Axsome Therapeutics, INC. | $48.29 | 2025 | Symbravo |
| Glaxosmithkline, LLC. | $47.11 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $40.84 | 2024 | Eterna, Proclaim |
| Merck Sharp & Dohme LLC | $38.12 | 2020-2021 | |
| Dexcom, INC. | $37.64 | 2024 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $36.05 | 2024 | |
| Currax Pharmaceuticals LLC | $32.66 | 2024-2025 | Contrave |
| Biohaven Pharmaceuticals, INC. | $29.43 | 2021 | |
| Pfizer INC. | $22.71 | 2025 | |
| Alvogen INC | $22.17 | 2023 | Teriparatide |
| Teva Pharmaceuticals USA, INC. | $22.17 | 2025 | Austedo Xr |
| Averitas Pharma INC. | $19.46 | 2025 | Qutenza |
| Genentech USA, INC. | $19.37 | 2019 | |
| Eisai INC. | $18.31 | 2021 | |
| Althera Pharmaceuticals LLC | $9.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roya Azadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.